Novo Nordisk’s Pipeline Plan Fails to Ease Patent-Cliff Concerns as Shares Slide

Novo’s Long-Term Drug Pipeline Meets Near-Term Investor Skepticism

Novo Nordisk (NVO) fell roughly 8% Monday as investors reacted to its capital markets day, where management laid out an expanded drug pipeline but provided limited additional clarity on near-term growth and the company’s transition through upcoming semaglutide patent expirations.

Novo plans to launch at least five potential “multi-blockbusters” by 2030 and is targeting more than 150 billion Danish kroner, or roughly $23 billion, in pipeline drug sales by 2035. The strategy comes as competition with Eli Lilly (LLY) intensifies and investors focus on what will replace growth from Ozempic and Wegovy as patent protection expires.

Key Points

• Novo Nordisk shares fell roughly 8% after its capital markets day failed to provide the level of growth visibility investors were seeking.
• Novo is targeting more than $23 billion in pipeline drug sales by 2035 and plans at least five potential multi-blockbuster launches by 2030.
• Investors remain focused on competition from Eli Lilly and the approaching loss of major patent protection for semaglutide, the main ingredient in Ozempic and Wegovy.

Novo Lays Out Its Plan Beyond Ozempic and Wegovy

Novo’s capital markets day centered on building a broader portfolio capable of supporting the company as its current obesity and diabetes franchise matures.

Management said it plans to launch at least five potential multi-blockbusters by the end of 2030. A multi-blockbuster is a drug expected to generate more than $1 billion in peak annual sales. Novo also aims to have around a dozen drug candidates in late-stage trials by 2030.

Obesity and diabetes remain central to the pipeline. Novo plans to launch its CagriSema injectable early next year, followed by high-dose CagriSema and stand-alone cagrilintide in 2028. Another candidate, zenagamtide, is expected to follow, with Novo planning to launch oral and injectable versions simultaneously.

The company is also expanding beyond obesity-linked conditions. Management outlined plans to develop treatments in areas including sickle-cell disease, endocrine disorders, blood disorders and ATTR-cardiomyopathy.

By 2035, Novo is targeting more than 150 billion Danish kroner, or approximately $23 billion, in sales from pipeline drugs. The company said that target excludes potential contributions from future acquisitions.

Dealmaking could become a larger part of the strategy. Novo indicated that its balance sheet could support larger acquisitions, while CEO Mike Doustdar has also discussed partnerships and acquisitions as ways to complement the company’s internal pipeline.

Why Did Novo Nordisk Stock Fall?

The selloff reflected the gap between Novo’s long-term pipeline ambitions and the growth visibility investors were seeking from the event.

Novo said revenue is expected to grow roughly in line with other large pharmaceutical companies through the end of the decade. Investors, however, were looking for more visibility into 2032, when Ozempic and Wegovy are expected to lose patent protection in the U.S.

Those two drugs accounted for roughly two-thirds of Novo’s sales last year, making the transition beyond semaglutide particularly important.

Patent protection has already expired or lapsed in Canada, India, Brazil and Turkey, while semaglutide is losing exclusivity in China this year. Major protection in Europe and the U.S. runs into the early 2030s.

Doustdar described the patent cliff as the “elephant in the room” and acknowledged the pricing pressure that accompanies generic competition. He also said lower prices can generate higher volumes, pointing to Novo’s experience in generic insulin.

The company’s current operating outlook adds to the uncertainty. Its most recent guidance calls for adjusted sales to decline by as much as 6% at constant exchange rates this year.

The market reaction was concentrated largely in Novo. While NVO fell about 8%, Lilly was modestly higher in the supplied market snapshots, and the broader S&P 500 was also higher.

Novo shares are now down roughly 22% year to date and about 73% from their June 2024 all-time high.

Can Novo Build Its Next Growth Engine Before the Patent Cliff?

Novo’s challenge is not simply developing additional drugs. The company needs its pipeline to become increasingly important as semaglutide approaches major patent expirations and competition in weight-loss treatments intensifies.

The company has already experienced setbacks. An experimental cardiovascular drug failed to produce the expected reduction in heart attack or stroke risk, while CagriSema disappointed on blood-sugar reduction compared with Lilly’s tirzepatide, according to analysts cited in the supplied material.

At the same time, Novo’s recently launched Wegovy pill has provided a more encouraging signal. Early prescription data showed it ahead of Lilly’s competing product, and Doustdar has said its early performance gives him hope that Novo can regain some lost market share.

Management is also restructuring the organization. Doustdar said he is trying to simplify Novo and increase urgency and efficiency. The supplied material reports significant job reductions as part of those efforts.

The longer-term strategy is therefore broader than finding a single replacement for Ozempic or Wegovy. Novo is attempting to expand its obesity portfolio, move additional treatments into late-stage development, diversify into other therapeutic areas and supplement internal research through partnerships and acquisitions.

What It Means for Investors

Monday’s decline shows that the market is placing significant weight on the period between Novo’s current semaglutide-driven business and the potential commercial contribution of its next generation of drugs.

The company provided substantial long-term pipeline targets: at least five potential multi-blockbusters by 2030, roughly a dozen late-stage candidates and more than $23 billion in pipeline sales targeted for 2035. But those objectives did not resolve the shorter-term questions surrounding competition, pricing and patent expirations.

The comparison with Lilly remains especially important because both companies compete in the weight-loss market. Novo was first to market with injectable and oral treatments, but Lilly has gained ground with Mounjaro and Zepbound, while Novo is now trying to build momentum behind its Wegovy pill and future obesity drugs.

The next phase of the Novo Nordisk story therefore centers on execution: the performance of newer products, progress through late-stage trials, the company’s ability to diversify its revenue base and how the business navigates declining semaglutide exclusivity.

Conclusion

Novo Nordisk used its capital markets day to present a broader vision for growth beyond its current obesity and diabetes blockbusters, but investors were looking for more clarity on the transition.

The company plans at least five potential multi-blockbuster launches by 2030 and is targeting more than $23 billion in pipeline drug sales by 2035. It is also expanding into additional therapeutic areas and considering acquisitions and partnerships to strengthen its pipeline.

Yet the roughly 8% decline in NVO stock underscores the immediate concerns surrounding the company: intensifying competition, slower current growth, pipeline execution and the approaching patent cliff for semaglutide. The progress of Novo’s next generation of treatments will determine how much of its long-term pipeline strategy translates into commercial growth.

FAQs

Why did Novo Nordisk stock fall?

Novo Nordisk shares fell roughly 8% after its capital markets day as investors looked for more clarity on near-term growth and the company’s strategy for navigating upcoming semaglutide patent expirations.

What is Novo Nordisk targeting from its drug pipeline?

Novo Nordisk is targeting more than 150 billion Danish kroner, or roughly $23 billion, in pipeline drug sales by 2035. The target excludes potential contributions from future acquisitions.

How many new blockbuster drugs does Novo Nordisk plan to launch?

Novo Nordisk plans to launch at least five potential multi-blockbusters by the end of 2030 and aims to have around a dozen candidates in late-stage trials by that time.

Why is the semaglutide patent cliff important for Novo Nordisk?

Semaglutide is the main ingredient in Ozempic and Wegovy, which accounted for roughly two-thirds of Novo’s sales last year. Major patent protection in Europe and the U.S. runs into the early 2030s.

What obesity drugs are next in Novo Nordisk’s pipeline?

Novo plans to launch CagriSema injectable early next year, followed by high-dose CagriSema and stand-alone cagrilintide in 2028. The company also plans to advance zenagamtide in oral and injectable forms.

This article was created with AI assistance and reviewed by an editor. For details, please refer to our Terms of Use.

Go Beyond the Market Brief with Market Edge

Follow SharperTrades’ complete approach to trading and investing, combining active trade opportunities through Block Orders, long-term research through Stock Investor, and structured market education through the Swing Trading Masterclass. Try Market Edge for $19 your first month →

Explore Research with Stock Investor

Stock Investor is SharperTrades’ platform for long-term investing research and portfolio management. Members receive research reports, portfolio updates, conviction tracking, and in-depth analysis designed to support disciplined investment decisions.

Explore Active Trading & Income Strategies

Block Orders tracks institutional activity and highlights active trade setups and price behavior across long and short opportunities.

For options-focused traders, Essential Option Income provides a structured approach to options income strategies, while Pro Option Trader offers a broader range of options strategies and trade opportunities.

Think More Clearly with SteadyCapital

SteadyCapital is SharperTrades’ decision-support system for long-term investors, built around the SteadyCapital Method™. Review investment ideas, challenge assumptions, evaluate valuation and risk, compare companies, and think through important buy, hold, add, trim, or sell decisions before you act.

Risk Disclosure

All content is provided for educational purposes only and does not constitute investment advice. Trading involves risk, and past performance is not indicative of future results. Please review our full Risk Disclosure for additional information.